BIOMAT Database Logo BIOMAT Database Logo

Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin. 1998

T Fukushima, and H Inoue, and H Takemura, and S Kishi, and T Yamauchi, and K Inai, and T Nakayama, and S Imamura, and Y Urasaki, and T Nakamura, and T Ueda
First Department of Internal Medicine, Fukui Medical University, Matsuoka, Japan.

We investigated the cytotoxicity and cellular pharmacology of idarubicin (IDA), idarubicinol (IDAol) and daunorubicin (DNR) in K562/VP-H2 cells, which show topoisomerase II-related multidrug resistance but do not overexpress P-glycoprotein. K562/VP-H2 cells were less resistant to IDA and IDAol than to DNR. There was no significant difference in the accumulation of each drug between K562 and K562/VP-H2 cells. The cleavage of DNA induced by each drug was decreased in K562/VP-H2 cells, however, the decrease in cleavage in K562/VP-H2 cells was less with IDA and IDAol than with DNR. These results suggest that IDA and IDAol have more cytotoxic potency than DNR in topoisomerase II-related multidrug-resistant leukemia cells.

UI MeSH Term Description Entries
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002457 Cell Extracts Preparations of cell constituents or subcellular materials, isolates, or substances. Cell Extract,Extract, Cell,Extracts, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003603 Cytotoxins Substances that are toxic to cells; they may be involved in immunity or may be contained in venoms. These are distinguished from CYTOSTATIC AGENTS in degree of effect. Some of them are used as CYTOTOXIC ANTIBIOTICS. The mechanism of action of many of these are as ALKYLATING AGENTS or MITOSIS MODULATORS. Cytolysins,Cytotoxic Agent,Cytotoxic Agents,Cytotoxin,Agent, Cytotoxic
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014343 Trypan Blue A diazo-naphthalene sulfonate that is widely used as a stain. Diamine Blue,Niagara Blue,VisionBlue,Blue, Diamine,Blue, Niagara,Blue, Trypan

Related Publications

T Fukushima, and H Inoue, and H Takemura, and S Kishi, and T Yamauchi, and K Inai, and T Nakayama, and S Imamura, and Y Urasaki, and T Nakamura, and T Ueda
Idarubicin more cost-effective than daunorubicin?
January 1992, PharmacoEconomics,
T Fukushima, and H Inoue, and H Takemura, and S Kishi, and T Yamauchi, and K Inai, and T Nakayama, and S Imamura, and Y Urasaki, and T Nakamura, and T Ueda
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
June 1999, Leukemia research,
T Fukushima, and H Inoue, and H Takemura, and S Kishi, and T Yamauchi, and K Inai, and T Nakayama, and S Imamura, and Y Urasaki, and T Nakamura, and T Ueda
Selected pharmacologic characteristics of idarubicin and idarubicinol.
January 1992, Leukemia,
T Fukushima, and H Inoue, and H Takemura, and S Kishi, and T Yamauchi, and K Inai, and T Nakayama, and S Imamura, and Y Urasaki, and T Nakamura, and T Ueda
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
November 1995, Biochemical pharmacology,
T Fukushima, and H Inoue, and H Takemura, and S Kishi, and T Yamauchi, and K Inai, and T Nakayama, and S Imamura, and Y Urasaki, and T Nakamura, and T Ueda
Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study.
March 1998, Biochimica et biophysica acta,
T Fukushima, and H Inoue, and H Takemura, and S Kishi, and T Yamauchi, and K Inai, and T Nakayama, and S Imamura, and Y Urasaki, and T Nakamura, and T Ueda
Liposome-encapsulated daunorubicin for PGP-related multidrug resistance.
July 1999, British journal of haematology,
T Fukushima, and H Inoue, and H Takemura, and S Kishi, and T Yamauchi, and K Inai, and T Nakayama, and S Imamura, and Y Urasaki, and T Nakamura, and T Ueda
Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis.
September 1997, Journal of chromatography. B, Biomedical sciences and applications,
T Fukushima, and H Inoue, and H Takemura, and S Kishi, and T Yamauchi, and K Inai, and T Nakayama, and S Imamura, and Y Urasaki, and T Nakamura, and T Ueda
Altered DNA topoisomerase II in multidrug resistance.
January 1993, Cytotechnology,
T Fukushima, and H Inoue, and H Takemura, and S Kishi, and T Yamauchi, and K Inai, and T Nakayama, and S Imamura, and Y Urasaki, and T Nakamura, and T Ueda
The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
July 1996, Blood,
T Fukushima, and H Inoue, and H Takemura, and S Kishi, and T Yamauchi, and K Inai, and T Nakayama, and S Imamura, and Y Urasaki, and T Nakamura, and T Ueda
Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
November 1994, Biochemical pharmacology,
Copied contents to your clipboard!